Letroblock® 2,5 mg

Description

Letrozole has anti-estrogenic activity, selectively inhibiting aromatase (an enzyme of estrogen synthesis) through highly specific competitive binding to the haem subunit of the cytochrome P450 of this enzyme. It blocks estrogen synthesis in both peripheral and tumour tissues.

Dosage form

Round biconvex tablets covered with a yellow coating. In cross-section, the core of the tablet is white or white with a yellowish tinge.

Composition

Each film-coated tablet contains:
active substance: letrozole – 2.50 mg;
excipients: lactose monohydrate – 50.00 mg, sodium carboxymethyl starch – 2.50 mg, colloidal silicon dioxide – 0.50 mg, microcrystalline cellulose – 28.00 mg, crospovidone – 4.00 mg, pregelatinised maize starch – 11.50 mg, magnesium stearate – 1.0 mg;
Coating: “Opadray Y 1-7000” [hypromellose, titanium dioxide, macrogol (polyethylene glycol)] – 3.73 mg, yellow iron oxide – 0.27 mg.
Pharmacotherapeutic group

Anticancer agent – estrogen synthesis inhibitor